As far as I know, SKI-606 is not active against T315I. Please look on this presentation:
http://www.hememalignancies.com/cml/bms_2005/pdf/shah.pdf Starting on slide 37, it talks about molecules not active against T315I. Starting on slide 38, it talks about 2 compounds that may be active against T315I. I believe VX-680 is already in the clinic (but don't know where). I have also heard of ceflatonin and its trial in T315I patients. Good luck, Shane On 4/18/06, anjana <[EMAIL PROTECTED]> wrote: > > SKI-606 in the lab shows some activity against T315I, trials have just > started at MDACC. These are Phase I trials. Also, Ceflatonin (more > commonly known as Homoharringtonine) trials for T315I patients to start > soon in the latter part of the year. If you go to > http://www.cmlhope.com and click on Clinical Trials and search for > SKI-606, you will get the trial information. SKI-606 is a BCR-ABL/SRC > dual inhibitor like Dasatinib but has better activity in the lab > against T315I. > > Other T315I drugs are in preclinical studies in the lab. > > Best Wishes, > Anjana > > > > > --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
